Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

724.51 -7.69 (-1.05%)
Streaming Delayed Price Updated: 10:11 AM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9 Next >
BioMedNewsBreaks — BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Positioned Favorably with Worldwide License to Anti-IL-17 NanoAbs
Via Investor Brand Network
Exposures Product Safety
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?
Pharmaceutical stocks are holding steady as Medicare price negotiations approach, but industry diversification and innovation support future growth prospects. 
Via MarketBeat
Topics Economy
Exposures Interest Rates
Sex Hormones Market to See Huge Growth by 2028 : Novartis, Sanofi, AstraZeneca, Merck
Sex Hormones- Comprehensive Study by Type (Progesterone, Testosterone, Drospirenone), Application (Topical, Inhalation, Injection, Others) Players and Region - Global Market Outlook to 2027 
Via SBWire
Eli Lilly and Company (NYSE: LLY) is a Stock Spotlight on 8/21
Via Investor Brand Network
Eli Lilly and Company (NYSE: LLY) Climbs to New 52-Week High
Via Investor Brand Network
Eli Lilly and Company (NYSE: LLY) Records 52-Week High Wednesday Morning
Via Investor Brand Network
Why These 3 Large Caps Are Bucking the August Slump
The three largest S&P 500 outperformers of August are tacking on gains in a weak market, making them intriguing momentum plays to watch for the rest of 2023. 
Via MarketBeat
Topics Economy Stocks
Exposures Fossil Fuels Interest Rates US Equities
Addiction Treatment Market May See New Emerging Trends: Novartis, Pfizer, Sanofi
Pune, Maharashtra -- (SBWIRE) -- 08/17/2023 -- 2023-2031 Report on Global Addiction Treatment Market by Player, Region, Type, Application and Sales Channel is the latest research study released by HTF... 
Via SBWire
Polypeptide.ltd Announces Intent to Expand Tirzepatide and Retatrutide to Production Capacity of High-Quality Peptides
Via Press Release Distribution Service
Eli Lilly and Company (NYSE: LLY) Making Surprising Moves in Friday Session
Via Investor Brand Network
Eli Lilly and Company (NYSE: LLY) Sets New 52-Week High in Wednesday Session
Via Investor Brand Network
Polypeptide.ltd Announces Intent to Expand Tirzepatide and Retatrutide to Production Capacity of High-Quality Peptides.
Moscow, Russia--(Newsfile Corp. - August 16, 2023) - Polypeptide.ltd, a frontrunner in delivering exceptional peptide services, proudly announces a substantial... 
Via Newsfile
Drinks, Chips & Drugs: A Surprising List of 10-Year Stock Winners
A handful of large caps have taken things to another level. These three stocks have blown past the herd — and may be market leaders for years to come. 
Via MarketBeat
Topics Bankruptcy Economy
Exposures Economy Financial Legal
Novo Nordisk Soars To New High On Weight-Loss Drug Trial Results
Novo Nordisk's stock surged 16% on preliminary results of clinical trials showing its weight-loss drug Wegovy reduces risk of cardiovascular disease by 20%. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Biotech Market Update: Global Pharmaceuticals Market Expected to Reach $1.5 Trillion by Year’s End
EQNX::TICKER_START (NYSE:PTN),(NASDAQ:CRDF),(NASDAQ:BDRX),(NASDAQ:DRUG),(NYSE:LLY) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19
Longeveron Announces Key Additions To Its Leadership Team and Board As It Gears Up For Phase 2 Trials For Its Lead Drug Candidate For Several Conditions
By David Willey, Benzinga 
Via TheNewswire.com
Blockbuster Drugs Market Projected to Show Strong Growth : Celgene, Bristol-Myers Squibb, Pfizer
Get an extensive Blockbuster Drugs Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry. 
Via SBWire
Topics Intellectual Property
Exposures Intellectual Property
Rising Dividend Make Zoetis a Doggone Winner
Investors that typically focus on other large cap pharmaceutical plays may wish to consider an alternative bet on pets with shares of Zoetis. 
Via MarketBeat
MarketBeat Week in Review – 7/24 - 7/28
Investors continue to look for stocks to buy as inflation cools. As you prepare for another busy week, here are some of our top stories from this week 
Via MarketBeat
Topics Economy
Exposures Interest Rates
M&A Activity, Booming Sales of Anti-IL-17 Drugs Suggest Strong Upside Potential for BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Lifestyle Drugs Market to See Huge Growth by 2028 : Alkermes, AstraZeneca, Pfizer, BMS
Lifestyle Drugs Comprehensive Study by Type (Depression, Dermatology, Sexual dysfunction, Obesity), Application (Children, Adults, Senior Citizens), Form (Tablets, External Use, Injection) Players and... 
Via SBWire
Exposures Product Safety
Lilly Shares Up On Versanis Deal Amid Weight-Loss Drug Gold Rush
A bid to acquire Versanis boosts Eli Lilly & Co. by 2.80% in the past week, as the competition to develop the most effective weight-loss drug intensifies. 
Via MarketBeat
Acumen Soars on Alzheimer's Study...Street Sees It Doubling
Will the $11.00 level be a double-top ceiling…or can Acumen Pharmaceuticals build momentum and climb towards its $25.00 IPO price? 
Via MarketBeat
Topics Initial Public Offering
Exposures Securities Market
Biogen Shares Fall After FDA Approval Of Alzheimer's Drug Leqembi
Biogen's shares decline after approval of Alzheimer's treatment Leqembi, which modestly slows cognitive decline. Analysts see hurdles to the rollout. 
Via MarketBeat
Exposures Product Safety
Extensive-Stage Small Cell Lung Cancer (ESCLC) Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Eli Lilly, Genentech, BioNTech, Xencor, Celgene
Via AB Newswire
Exposures Product Safety
Alopecia Market expected to rise | Companies – Stiefel, GlaxoSmithKline, Eli Lilly and Company, Incyte Corporation, Energenesis Biomedical Co., expected to drive market
Via AB Newswire
Inflammatory Bowel Disease Market expected to rise | Companies – Eli Lilly and Company, Gilead, Galapagos, Protagonist Therapeutics, Athos Therapeutics, expected to drive market
Via AB Newswire
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Names New COO, Announces Participation in Upcoming London Symposium
Via Investor Brand Network
Exposures Product Safety
Verve Therapeutics Gains 20.74% In June as Ark Funds Invest
Verve Therapeutics' efforts to eliminate cardiovascular disease through gene-editing treatments have momentum, as the stock gets a 20.74% boost in June. 
Via MarketBeat
Promising Small Biotech Amphastar Sees Actionable Pullback
Small-cap Amphastar Pharmaceuticals is pulling back from recent highs in an orderly fashion, potentially offering a new entry point after beating Q1 views. 
Via MarketBeat
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.